BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26715915)

  • 1. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.
    Thomas AL; Coarfa C; Qian J; Wilkerson JJ; Rajapakshe K; Krett NL; Gunaratne PH; Rosen ST
    Nucl Recept Signal; 2015; 13():e006. PubMed ID: 26715915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells.
    Palagani A; Op de Beeck K; Naulaerts S; Diddens J; Sekhar Chirumamilla C; Van Camp G; Laukens K; Heyninck K; Gerlo S; Mestdagh P; Vandesompele J; Berghe WV
    PLoS One; 2014; 9(12):e113842. PubMed ID: 25474406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.
    Grugan KD; Ma C; Singhal S; Krett NL; Rosen ST
    J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):244-54. PubMed ID: 18499442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.
    Tessel MA; Benham AL; Krett NL; Rosen ST; Gunaratne PH
    Horm Cancer; 2011 Jun; 2(3):182-9. PubMed ID: 21761344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression.
    Medh RD; Saeed MF; Johnson BH; Thompson EB
    Cancer Res; 1998 Aug; 58(16):3684-93. PubMed ID: 9721879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.
    Clarisse D; Prekovic S; Vlummens P; Staessens E; Van Wesemael K; Thommis J; Fijalkowska D; Acke G; Zwart W; Beck IM; Offner F; De Bosscher K
    Cell Mol Life Sci; 2023 Aug; 80(9):249. PubMed ID: 37578563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.
    Huang X; Yang M; Jin J
    Leuk Lymphoma; 2012 Jun; 53(6):1188-95. PubMed ID: 22260163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA.
    Moalli PA; Pillay S; Weiner D; Leikin R; Rosen ST
    Blood; 1992 Jan; 79(1):213-22. PubMed ID: 1728309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).
    Sánchez-Vega B; Gandhi V
    Br J Haematol; 2009 Mar; 144(6):856-64. PubMed ID: 19133980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.
    Kervoëlen C; Ménoret E; Gomez-Bougie P; Bataille R; Godon C; Marionneau-Lambot S; Moreau P; Pellat-Deceunynck C; Amiot M
    Oncotarget; 2015 Sep; 6(29):26922-34. PubMed ID: 26323097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [P38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
    He L; Li D; Hou KZ; Liu YP
    Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia.
    Ploner C; Schmidt S; Presul E; Renner K; Schröcksnadel K; Rainer J; Riml S; Kofler R
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):153-60. PubMed ID: 15860257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis and modeling of glucocorticoid-controlled gene expression.
    Chen DW; Lynch JT; Demonacos C; Krstic-Demonacos M; Schwartz JM
    Pharmacogenomics; 2010 Nov; 11(11):1545-60. PubMed ID: 21121775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA.
    Gomi M; Moriwaki K; Katagiri S; Kurata Y; Thompson EB
    Cancer Res; 1990 Mar; 50(6):1873-8. PubMed ID: 2106390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells.
    Sánchez-Vega B; Krett N; Rosen ST; Gandhi V
    Mol Cancer Ther; 2006 Dec; 5(12):3062-70. PubMed ID: 17172408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies.
    Clarisse D; Van Wesemael K; Tavernier J; Offner F; Beck IM; De Bosscher K
    PLoS One; 2018; 13(5):e0197000. PubMed ID: 29738549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression.
    Geley S; Hartmann BL; Hala M; Strasser-Wozak EM; Kapelari K; Kofler R
    Cancer Res; 1996 Nov; 56(21):5033-8. PubMed ID: 8895760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.